Scientific Reports · 2019 · 38 citations · 59 references
PharmacyPharmaceuticsPharmacologyChemotherapyDrug DeliveryNanoparticle Drug DeliveryChemotherapy Drug AdministrationNanoparticle DesignOvarian CancerOvarian Cancer PharmacotherapyControlled ReleaseControlled Release MaterialsLocalizing Recurrent DiseaseMicrospheresNanocarrier-mediated PermeationNanoparticle-based ChemotherapyOvarian Cancer ChemotherapyRecurrent Ovarian Cancer
Abstract Patients with advanced ovarian cancer develop recurrence despite initial treatment response to standard treatment of surgery and intravenous/intraperitoneal (IP) chemotherapy, partly due to a limited peritoneal exposure time of chemotherapeutics. Paclitaxel-loaded genipin-crosslinked gelatin microspheres (PTX-GP-MS) are evaluated for the treatment of microscopic peritoneal carcinomatosis and prevention of recurrent disease. The highest drug load (39.2 µg PTX/mg MS) was obtained by immersion of GP-MS in aqueous PTX nanosuspension (PTX nano -GP-MS) instead of ethanolic PTX solution (PTX EtOH -GP-MS). PTX release from PTX-GP-MS was prolonged. PTX nano -GP-MS displayed a more controlled release compared to a biphasic release from PTX EtOH -GP-MS. Anticancer efficacy of IP PTX-GP-MS (PTX EtOH -GP-MS, D = 7.5 mg PTX/kg; PTX nano -GP-MS D = 7.5 and 35 mg PTX/kg), IP nanoparticular albumin-bound PTX (D = 35 mg PTX/kg) and controls (0.9% NaCl, blank GP-MS) was evaluated in a microscopic peritoneal carcinomatosis xenograft mouse model. PTX nano -GP-MS showed superior anticancer efficacy with significant increased survival time, decreased peritoneal carcinomatosis index score and ascites incidence. However, prolonged PTX release over 14 days from PTX nano -GP-MS caused drug-related toxicity in 27% of high-dosed PTX nano -GP-MS-treated mice. Dose simulations for PTX nano -GP-MS demonstrated an optimal survival without drug-induced toxicity in a range of 7.5–15 mg PTX/kg. Low-dosed PTX nano -GP-MS can be a promising IP drug delivery system to prevent recurrent ovarian cancer.
59
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2017 · 15K citations · Full text
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel et al. · New England Journal of Medicine · 2006 · 2.6K citations · Full text
Medicine, Gynecology, Oncology +14
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Willemien J. van Driel, Simone N. Koole, Karolina Sikorska et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text
David S. Alberts, P. Y. Liu, Edward V. Hannigan et al. · New England Journal of Medicine · 1996 · 1.2K citations · Full text
Maurie Markman, Brian N. Bundy, David S. Alberts et al. · Journal of Clinical Oncology · 2001 · 1.1K citations
Medicine, Oncology, Pharmacotherapy +15